Abstract
A number of new antibacterial fluoroquinolones derived from nalidixic acid, including norfloxacin, ciprofloxacin, ofloxacin, enoxacin, and lomefloxacin, have been approved during the past 7 years. Fleroxacin, yet to be released for use in the U.S., has excellent absorption and bioavailability, good tissue penetration, and low protein binding. Because the drug is slowly metabolized, once-a-day oral dosing is effective. A symposium on fleroxacin reported …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
